Old Web
English
Sign In
Acemap
>
authorDetail
>
Johanna C. Bendell
Johanna C. Bendell
Medicine
Pathology
Cancer
Family medicine
Common Terminology Criteria for Adverse Events
4
Papers
53
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
2017
Oncologist
Johanna C. Bendell
Howard S. Hochster
Lowell L Hart
Irfan Firdaus
Joseph R. Mace
Joshua J. McFarlane
Mark Kozloff
Daniel V.T. Catenacci
Jessie J. Hsu
Stephen Paul Hack
David S. Shames
See-Chun Phan
Hartmut Koeppen
Allen Lee Cohn
Show All
Source
Cite
Save
Citations (28)
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
2015
Cancer
Johanna C. Bendell
Manish R. Patel
Jeffrey R. Infante
Carla Kurkjian
Suzanne F. Jones
Shubham Pant
Howard A. Burris
Ofir Moreno
Vanessa Esquibel
Wendy Levin
Kathleen N. Moore
Show All
Source
Cite
Save
Citations (20)
Donating Tissue for Research: Patient and Provider Perspectives
2011
Journal of Oncology Practice
Allison R. Baer
Mary Lou Smith
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (5)
Cancer Genomics: Conducting Exemplary Trials With Biospecimen and Biomarker Components
2010
Journal of Oncology Practice
Allison R. Baer
Deborah Collyar
Mary Lou Smith
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (0)
1